Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Myeloma

Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations

Leukemia volume 20, pages 807–813 (2006)Cite this article

Abstract

Chromosomal hyperdiploidy is the defining genetic signature in 40–50% of myeloma (MM) patients. We characterize hyperdiploid-MM (H-MM) in terms of its clinical and prognostic features in a cohort of 220 H-MM patients entered into clinical trials. Hyperdiploid-myeloma is associated with male sex, kappa immunoglobulin subtype, symptomatic bone disease and better survival compared to nonhyperdiploid-MM (median overall survival 48 vs 35 months, log-rank P=0.023), despite similar response to treatment. Among 108 H-MM cases with FISH studies for common genetic abnormalities, survival is negatively affected by the existence of immunoglobulin heavy chain (IgH) translocations, especially those involving unknown partners, while the presence of chromosome 13 deletion by FISH did not significantly affect survival (median overall survival 50 vs 47 months, log-rank P=0.47). Hyperdiploid-myeloma is therefore a unique genetic subtype of MM associated with improved outcome with distinct clinical features. The existence of IgH translocations but not chromosome 13 deletion by FISH negatively impacts survival and may allow further risk stratification of this population of MM patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Bergsagel PL, Chesi M, Nardini E, Brents LA, Kirby SL, Kuehl WM . Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci USA 1996; 93: 13931–13936.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Chesi M, Bergsagel PL, Brents LA, Smith CM, Gerhard DS, Kuehl WM . Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood 1996; 88: 674–681.

    CAS  PubMed  Google Scholar 

  3. Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997; 16: 260–264.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL . The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 1998; 92: 3025–3034.

    CAS  PubMed  Google Scholar 

  5. Chesi M, Bergsagel PL, Shonukan OO, Martelli ML, Brents LA, Chen T et al. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 1998; 91: 4457–4463.

    CAS  PubMed  Google Scholar 

  6. Smadja NV, Fruchart CC, Isnard F, Louvet C, Dutel JL, Cheron N et al. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia 1998; 12: 960–969.

    Article  CAS  PubMed  Google Scholar 

  7. Debes-Marun CS, Dewald GW, Bryant S, Picken E, Santana-Davila R, Gonzalez-Paz N et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 2003; 17: 427–436.

    Article  CAS  PubMed  Google Scholar 

  8. Fonseca R, Debes-Marun CS, Picken EB, Dewald GW, Bryant SC, Winkler JM et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 2003; 102: 2562–2567.

    Article  CAS  PubMed  Google Scholar 

  9. Fonseca R, Oken MM, Greipp PR . The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance. Blood 2001; 98: 1271–1272.

    Article  CAS  PubMed  Google Scholar 

  10. Chng WJ, Van Wier SA, Ahmann GJ, Winkler JM, Jalal SM, Bergsagel PL et al. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood 2005; 106: 2156–2161.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart CC . Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001; 98: 2229–2238.

    Article  CAS  PubMed  Google Scholar 

  12. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101: 4569–4575.

    Article  CAS  PubMed  Google Scholar 

  13. Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau JL et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002; 100: 1579–1583.

    Article  CAS  PubMed  Google Scholar 

  14. Shaughnessy J, Jacobson J, Sawyer J, McCoy J, Fassas A, Zhan F et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood 2003; 101: 3849–3856.

    Article  CAS  PubMed  Google Scholar 

  15. Fassas AB, Spencer T, Sawyer J, Zangari M, Lee CK, Anaissie E et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol 2002; 118: 1041–1047.

    Article  CAS  PubMed  Google Scholar 

  16. Fonseca R, Blood EA, Oken MM, Kyle RA, Dewald GW, Bailey RJ et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood 2002; 99: 3735–3741.

    Article  CAS  PubMed  Google Scholar 

  17. Fonseca R, Harrington D, Oken MM, Dewald GW, Bailey RJ, Van Wier SA et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study. Cancer Res 2002; 62: 715–720.

    CAS  PubMed  Google Scholar 

  18. Chang H, Sloan S, Li D, Zhuang L, Yi QL, Chen CI et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 2004; 125: 64–68.

    Article  PubMed  Google Scholar 

  19. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy Jr J . Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005; 106: 296–303.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Oken MM, Leong T, Lenhard Jr RE, Greipp PR, Kay NE, Van Ness B et al. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486. Cancer 1999; 86: 957–968.

    Article  CAS  PubMed  Google Scholar 

  21. Greipp PR, Lust JA, O'Fallon WM, Katzmann JA, Witzig TE, Kyle RA . Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993; 81: 3382–3387.

    CAS  PubMed  Google Scholar 

  22. Greipp PR, Leong T, Bennett JM, Gaillard JP, Klein B, Stewart JA et al. Plasmablastic morphology--an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood 1998; 91: 2501–2507.

    CAS  PubMed  Google Scholar 

  23. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–3420.

    Article  PubMed  Google Scholar 

  24. Fonseca R, Trendle MC, Leong T, Kyle RA, Oken MM, Kay NE et al. Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. Br J Haematol 2000; 109: 24–29.

    Article  CAS  PubMed  Google Scholar 

  25. Ahmann GJ, Jalal SM, Juneau AL, Christensen ER, Hanson CA, Dewald GW et al. A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. Cancer Genet Cytogenet 1998; 101: 7–11.

    Article  CAS  PubMed  Google Scholar 

  26. Fonseca R, Bailey RJ, Ahmann GJ, Rajkumar SV, Hoyer JD, Lust JA et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 2002; 100: 1417–1424.

    CAS  PubMed  Google Scholar 

  27. Fonseca R, Oken MM, Harrington D, Bailey RJ, Van Wier SA, Henderson KJ et al. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia 2001; 15: 981–986.

    Article  CAS  PubMed  Google Scholar 

  28. Greipp PR, Trendle MC, Leong T, Oken MM, Kay NE, Van Ness B et al. Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma? Leuk Lymphoma 1999; 35: 83–89.

    Article  CAS  PubMed  Google Scholar 

  29. Jacobson JL, Hussein MA, Barlogie B, Durie BG, Crowley JJ . A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol 2003; 122: 441–450.

    Article  PubMed  Google Scholar 

  30. Durie BG, Stock-Novack D, Salmon SE, Finley P, Beckord J, Crowley J et al. Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study. Blood 1990; 75: 823–830.

    CAS  PubMed  Google Scholar 

  31. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A . C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992; 80: 733–737.

    CAS  PubMed  Google Scholar 

  32. Robbiani DF, Chesi M, Bergsagel PL . Bone lesions in molecular subtypes of multiple myeloma. N Engl J Med 2004; 351: 197–198.

    Article  CAS  PubMed  Google Scholar 

  33. Chang H, Stewart AK, Qi XY, Li ZH, Yi QL, Trudel S . Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. Blood 2005; 106: 353–355.

    Article  CAS  PubMed  Google Scholar 

  34. Keats JJ, Reiman T, Maxwell CA, Taylor BJ, Larratt LM, Mant MJ et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 2003; 101: 1520–1529.

    Article  CAS  PubMed  Google Scholar 

  35. Garcia-Sanz R, Orfao A, Gonzalez M, Moro MJ, Hernandez JM, Ortega F et al. Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients. Castelano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies. Br J Haematol 1995; 90: 106–112.

    Article  CAS  PubMed  Google Scholar 

  36. Winkler JM, Greipp P, Fonseca R . t(4;14)(p16.3;q32) is strongly associated with a shorter survival in myeloma patients. Br J Haematol 2003; 120: 170–171.

    Article  PubMed  Google Scholar 

  37. Chang H, Qi C, Yi QL, Reece D, Stewart AK . p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 2005; 105: 358–360.

    Article  CAS  PubMed  Google Scholar 

  38. Drach J, Ackermann J, Fritz E, Kromer E, Schuster R, Gisslinger H et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 1998; 92: 802–809.

    CAS  PubMed  Google Scholar 

  39. Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Litzow MR, Henderson KJ et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005; 106: 2837–2840.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Rajkumar SV, Fonseca R, Dewald GW, Therneau TM, Lacy MQ, Kyle RA et al. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet 1999; 113: 73–77.

    Article  CAS  PubMed  Google Scholar 

  41. Dewald GW, Kyle RA, Hicks GA, Greipp PR . The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 1985; 66: 380–390.

    CAS  PubMed  Google Scholar 

  42. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004; 64: 1546–1558.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

RF is a Clinical Investigator of the Damon Runyon Cancer Research Fund. This work was supported by the Donaldson Charitable Trust, the International Waldenström Macroglobulinemia Foundation, and Grants R01 CA83724-01, SPORE P50 CA100707-01and P01 CA62242 from the National Cancer Institute, and the Fund to Cure Myeloma. PRG is supported by the ECOG Grant CA21115-25C from the National Cancer Institute. WJC is funded by an International Fellowship from the Agency for Science, Technology and Research (A*STAR), Singapore.

Author information

Authors and Affiliations

  1. Division of Hematology-Oncology, Mayo Clinic Scottsdale, AZ, USA

    W J Chng, S A Van Wier, G J Ahmann, P L Bergsagel, M Chesi & R Fonseca

  2. Division of Hematology, MN, USA

    R Santana-Dávila, K Henderson, R A Kyle, M A Gertz, M Q Lacy, A Dispenzieri & P R Greipp

  3. Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, MN, USA

    S M Jalal

  4. Missouri Cancer Associates, MO, USA

    M C Trendle

  5. Eastern Cooperative Oncology Group Statistical Center, Dana Farber Cancer Institute, MA, USA

    S Jacobus & E Blood

  6. North Memorial Cancer Center, MN, USA

    M M Oken

  7. Department of Haematology-Oncology, National University Hospital, Singapore, Singapore

    W J Chng

Authors
  1. W J Chng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Santana-Dávila
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S A Van Wier
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G J Ahmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S M Jalal
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P L Bergsagel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Chesi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M C Trendle
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S Jacobus
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. E Blood
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M M Oken
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. K Henderson
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. R A Kyle
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. M A Gertz
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. M Q Lacy
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. A Dispenzieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. P R Greipp
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. R Fonseca
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Fonseca.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chng, W., Santana-Dávila, R., Van Wier, S. et al. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia 20, 807–813 (2006). https://doi.org/10.1038/sj.leu.2404172

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404172

Keywords

This article is cited by

Search

Advanced search

Quick links